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Thangjam GS, Birmpas C, Barabutis N, Gregory BW, Clemens
MA, Newton JR, Fulton D, Catravas JD. Hsp90 inhibition sup-
presses NF-B transcriptional activation via Sirt-2 in human lung
microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol
310: L964 –L974, 2016. First published April 1, 2016;
doi:10.1152/ajplung.00054.2016.—The ability of anti-heat shock pro-
tein 90 (Hsp90) drugs to attenuate NF-B-mediated transcription is
the major basis for their anti-inflammatory properties. While the
molecular mechanisms underlying this effect are not clear, they
appear to be distinct in human endothelial cells. We now show for the
first time that type 2 sirtuin (Sirt-2) histone deacetylase binds human
NF-B target gene promoter and prevents the recruitment of NF-B
proteins and subsequent assembly of RNA polymerase II complex in
human lung microvascular endothelial cells. Hsp90 inhibitors stabilize
the Sirt-2/promoter interaction and impose a “transcriptional block,”
which is reversed by either inhibition or downregulation of Sirt-2
protein expression. Furthermore, this process is independent of
NF-B (p65) Lysine 310 deacetylation, suggesting that it is distinct
from known Sirt-2-dependent mechanisms. We demonstrate that
Sirt-2 is recruited to NF-B target gene promoter via interaction with
core histones. Upon inflammatory challenge, chromatin remodeling
and core histone H3 displacement from the promoter region removes
Sirt-2 and allows NF-B/coactivator recruitment essential for RNA
Pol II-dependent mRNA induction. This novel mechanism may have
important implications in pulmonary inflammation.
human lung endothelial cells; NF-B; Sirt-2; histone h3; Hsp90
EXPOSURE TO BACTERIA THROUGH either inhalation or systemically
causes acute lung injury (ALI) in animals and humans (15, 22).
Lipopolysaccharide (LPS) binds to endothelial Toll-like recep-
tor 4 (TLR-4) and induces IKB phosphorylation leading to
ubiquitination and proteasomal degradation. NF-B exists in a
complex with the inhibitory IKB in the cytoplasm. Following
IKB degradation, NF-B is released and translocates into the
nucleus, where it binds its cognate promoters (10, 13). NF-B
regulates the expression of proinflammatory cytokines and cell
adhesion molecules on the surface of endothelial cells (6).
NF-B binding to the cognate promoter and transcriptional
activation of target genes are controlled by a complex set of
transcriptional co-regulators. NF-B coactivators serve as
bridges between the NF-B inducer and the RNA polymerase
II transcription initiation complexes (14, 28, 30), whereas
NF-B co-repressors destabilize the NF-B activator complex
at the target promoter (8). NF-B responsive promoters exhibit
a unique histone modification pattern of hyperacetylated core
histone H3 at K9. This allows rapid chromatin remodeling and
eviction of nucleosomes from the enhancer region that un-
masks obscured NF-B enhancer elements (19). We have
demonstrated that inhibition of this process by hsp90 inhibitor
suppresses gene expression (31).
The family of Sirtuins negatively impact NF-B signaling
(24, 33). Sirtuins deacetylate histones and nonhistone proteins
with equal efficiency (14). Seven types of sirtuins serve as
epigenetic transcriptional silencers (7, 18). Sirtuins attenuate
NF-B signaling via deacetylation of either NF-B subunits or
histone proteins at target promoter region (2, 17). Type 2
sirtuin (Sirt-2) is a tubulin deacetylase and predominantly
present in the cytoplasm (21). It interacts with p65 (NF-B
subunit) and deacetylates it at K310. This attenuates agonist-
mediated NF-B target gene expression (26).
The most common mechanism of NF-B regulation is by
posttranslational modifications (10). The phosphorylation of
p65 by MSK-1 or PKA kinase at Ser276 is essential for its
interaction with the p300/CBP coactivator (9, 25, 36). This
promotes the acetylation of NF-B by the histone acetylases
associated with p300/CBP. p65 acetylation at Ser276 and
Ser536 enhances its DNA binding efficiency and inhibits its
interaction with IKB (32). Previously, we reported that, in
human lung endothelial cells, the inhibition of NF-B by hsp90
inhibitors is independent of p65 Ser276 phosphorylation (31);
a more direct mechanism appears to be involved. For example,
the physical exclusion of NF-B from the promoter by gluco-
corticoid receptors effectively suppresses NF-B activation in
dexamethasone-treated pancreatic cancer cells (20). However,
this mechanism seems rather unlikely, since sirtuins lack func-
tional DNA binding domains (27, 34), although sirt-2 binds the
NEDD4 promoter at the transcription start site and thus blocks
retinoic acid receptor-mediated gene induction (16).
An important regulator of immune function and NF-B
signaling pathway is the 90 kDa heat shock protein (Hsp90).
We have earlier reported that the prototype hsp90 inhibitor,
17-AAG (17-N-allylamino-17-demethoxygeldanamycin), at-
tenuates NF-B transcription in human endothelial cells (31).
We now provides evidence of the involvement of Sirt-2 in this
process.
MATERIALS AND METHODS
Reagents and antibodies. Escherichia coli endotoxin (LPS) L-3137
was purchased from Sigma-Aldrich (St. Louis, MO). Hsp90 inhibitor
17-AAG was from Selleck Chemicals (Houston, TX). Sirtuin inhibi-
tors Sirtinol, AGK2, and EX527 were purchased from ENZO Life
Address for reprint requests and other correspondence: J. D. Catravas, Frank
Reidy Research Center for Bioelectrics, Old Dominion Univ., 4211 Monarch
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Am J Physiol Lung Cell Mol Physiol 310: L964–L974, 2016.
First published April 1, 2016; doi:10.1152/ajplung.00054.2016.
1040-0605/16 Copyright © 2016 the American Physiological Society http://www.ajplung.orgL964
 by 10.220.33.4 on M
ay 26, 2017
http://ajplung.physiology.org/
D
ow
nloaded from
 
Sciences (Farmingdale, NY). Anti-histone H3 mouse mAB (14269),
acetyl-histone H3 (Lys9) rabbit pAB (9649), and anti-PARP rabbit
pAB (9542) antibodies were purchased from Cell Signaling Technol-
ogy (Danvers, MA). ChIP grade anti-p65 rabbit pAB (ab7970),
anti-p65 (acetyl K310) rabbit pAB (52175), anti-Sirt-2 rabbit pAB
(ab67299), anti-Sirt-1 rabbit pAB (ab32441), anti-T7 goat pAB
(ab9138), and anti-Flag goat pAB (ab1257), antibodies were pur-
chased from Abcam (Cambridge, MA). Chromatin immunoprecipita-
tion (ChIP)-grade anti-RNA polymerase II mouse mAB (39097)
antibody was purchased from Active Motif (Carslbad, CA). Anti-beta-
actin mouse mAB (A2228) was purchased from Sigma Aldrich.
Anti-Hsp90 mouse mAB (6140419) was purchased from BD Biosci-
ences (San Jose, CA). Anti-alpha-tubulin mouse mAB (909603) was
from CRP (Covance Research Products, Denver, PA). Secondary
antibodies IRDye 800CW and IRDye 680RD were purchased from
Li-Cor (Lincoln, NE).
Cell culture. Human lung microvascular endothelial cells (HLM-
VEC) were isolated and cultured as described in Ref. 3. HeLa human
cervical carcinoma cells were a kind gift from Dr. Andrei Pakhomov
(Frank Reidy Research Center for Bioelectrics, Old Dominion Uni-
versity) and were cultured in high glucose Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, 100 IU
penicillin, and 100 g/ml streptomycin (CellGro Mediatech, Manas-
sas, VA). B16F10 mouse melanoma cells were a kind gift from Dr.
Loree Heller (Frank Reidy Research Center for Bioelectrics, Old
Dominion University) and were cultured in McCoy’s 5A (Iwakata &
Grace Modification) supplemented with 25 g/ml gentamicin (Cell-
gro, Mediatech) and 10% FBS.
Western blotting and coimmunoprecipitation. Western blotting and
coimmunoprecipitation were performed as described (31). Briefly,
treated cells were lysed in RIPA lysis buffer supplemented with
protease inhibitor cocktail V and phosphatase inhibitors (Sigma Al-
drich). Either 3–5 g normal IgG or antibody of interest was used for
immunoprecipitation for 1,000 g lysate. The immune complex was
collected with Protein A/G plus agarose beads (Santa Cruz Biotech-
nologies, Dallas, TX) and washed with lysis buffer. The immune
complex was then resolved on SDS-PAGE and transferred to the
nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA). Pro-
tein interaction was detected by immunoblotting with either normal
IgG or antibodies of interest. The signal was developed by using
Quick Western Kit IRDye 680RD (LI-Cor BioSciences, Lincoln, NE)
and developed using Li-Cor Odyssy CLx.
Immunofluorescence. We seeded 50  103 HLMVEC/well of
eight-well MiniCell cell culture plates (Millipore, Billerica, MA) and
grew them overnight. The cells were treated with 1 EU/ml LPS for
1 h with and without 5 g/ml 17-AAG (16 h pretreatment). The cells
were then fixed with 4% paraformaldehyde (Sigma Aldrich) for 10
min, permeabilized for 15 min in 0.5% Triton X-100 at room tem-
perature, and blocked with 3% BSA containing phosphate-buffered
saline for 1 h at room temperature, followed by 5 g/ml anti-rabbit
Sirt-2 antibody (ab67299) from Abcam. After being washed, the cells
were probed with 1:500 Alexa Fluor 488 anti-Rabbit IgG (H  L)
from Molecular Probes (Invitrogen, Eugene, OR) for 1 h at room
temperature, washed and mounted with a drop of Prolong Gold
Antifade Reagent with DAPI from Molecular Probes, Invitrogen.
Cells were observed using a FLUOVIEW FV1Oi confocal micro-
scope (Olympus American, Melville, NY).
NF-B luciferase reporter assay. NF-B firefly luciferase reporter
adenovirus was purchased from Vector Biolabs (Philadelphia, PA).
Green fluorescent protein (GFP)-expressing adenovirus was generated
and characterized as in (35). HLMVEC were cotransduced with
NF-B-Luc adenovirus [10 multiplicities of infection (MOI)] and
GFP adenovirus (100 MOI) in 96-well plates for 3 days and then
treated with 10 EU/ml LPS for 4 h in the presence and absence of
17-AAG (5 g/ml, 16 h pretreatment). Equal amounts of the lysate
were used in triplicate for determining GFP fluorescence (485/528
nm). Luminescence was measured using the Bright Glo Luciferase
reagent (Promega, Madison, WI) in a FluoStar Omega plate reader
(LabTech, Cary, NC) and normalized to GFP fluorescence.
Flag-Sirt-2 and T7-p65 overexpression in B16F10 mouse mela-
noma cells. B16F10 were transfected with pcDNA3.1-Flag Sirt-2 or
empty pcDNA3.1-Flag/HA vector purchased from Addgene (Cam-
bridge, MA). Cells were grown in 100 mm dishes and transfected with
10 g plasmid with 60 l Effectene transfection reagent (QIAGEN,
Valencia, CA). Next day, the cells were transduced with T7-p65
adenoviral particles as described in Ref. 13. After 3 days, the cells
were treated with LPS (1 EU/ml) for 1 h in the presence or absence of
17-AAG (16 h). Flag/Sirt-2 and T7-p65 expression levels were as-
sessed by Western blotting.
RNAi-mediated Sirt-2 downregulation in human lung endothelial
cells. HLMVEC were transduced with either control GFP or Sirt-2
shRNA lentiviral particles (10 MOI) from Santa Cruz Biotechnology
in 24-well tissue culture plates with 4 g/ml polybrene from Santa
Cruz Biotechnology in culture medium. On the 4th day, the cells were
treated with LPS (1 EU/ml) for 4 h in the presence and absence of
17-AAG (5 g/ml, 16 h). The downregulation of Sirt-2 mRNA
expression was determined by TaqMan real-time quantitative (q)PCR
(Applied Biosystems) and Sirt-2 protein expression by Western blot
analysis.
Sirt-2 activity assay. Sirt-2 activity assay was performed with
immunoprecipitated Sirt-2 using SIRT-Glo Assay kit (Promega).
Briefly, HLMVEC were grown in 150 mm dishes to 90% confluence
and treated with drugs for 16 h followed by LPS (1 EU/ml) for 30 min.
Cells were lysed in chilled Sirt assay buffer containing protease
inhibitors and centrifuged to discard the pellet. We immunoprecipi-
tated 1,000 g of cell lysate with 5 g anti Sirt-2 antibody (ab67299)
(Abcam) and 25 l of magnetic protein-G beads (Active Motif)
overnight at 4°C. The immune complex was washed three times with
1 ml of chilled NP-40 buffer (10 mM Tris·HCl pH 7.6, 150 mM NaCl,
and 0.1% NP-40) and finally washed with 200 l of Sirt assay buffer.
Sirt activity assay was performed with the immunoprecipitated Sirt-2
according to the supplier’s instruction. Reactions were performed in
triplicate, and the deacetylase activity that was inhibited by 1 mM
AGK2 (Sirt-2-specific inhibitor) was considered as Sirt-2 activity.
Real-time qPCR. Total cellular RNA was extracted with using
RNeasy Plus Micro Kit from Qiagen (Valencia, CA) and reverse
transcribed using random hexamer primers (High-Capacity cDNA
Reverse Transcription Kit from Applied Biosystems, Carlsbad, CA).
Real-time qPCR was performed using human IKB and GAPDH
TaqMan probes (Applied Biosystems) using StepOnePlus Real-Time
PCR System (Applied Biosystems). All reactions were performed in
triplicate; actin or GAPDH were used as internal standards.
ChIP assay. ChIP assays were performed using IT-Express ChIP
Assay Kit from Active Motif according to the supplier’s instructions.
Briefly, confluent HLMVEC were fixed in 1% formaldehyde and
sonicated in 350 l of shearing buffer. Approximately 14 –21 g
sonicated chromatin was immunoprecipitated with 2–3 g ChIP-
grade antibody overnight at 4°C. The immune complex was cap-
tured with magnetic protein-G beads. The eluted DNA was used
for amplification of human IKB promoter region using
forward: 5=-GGAATTTCCAAGCCAGTCAG-3= and reverse: 5=-
GAAGGACTTTCCAGCCACTC-3= primers. Human VEGF pro-
moter primers forward: 5=-CCTCAGTTCCCTGGCAACAT-
CTG-3= and reverse: 5=-GAAGAATTTGGCACCAAGTTTGT-3=
were used as negative control. PCR steps of 30–35 cycles were
performed at 50°C depending on the ChIP antibody using HotStart IT
Taq 2X PCR master mix from Affymetrix (Santa Clara, CA). The
amplified PCR products were resolved on ethidium bromide agarose
gel. The images were analyzed using ChemiDoc XRS System from
(Bio-Rad). We also used ImageJ (National Institute of Health,
Bethesda, MD) to determine DNA band intensity. The normalized
DNA band intensity was represented as fold change in the form of a
bar graph generated by GraphPad Prism 5 (La
Jolla, CA).
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In vivo experiments. We purchased 6 to 8 wk old male C57BL/6
mice from Harlan (Indianapolis, IN). Mice were maintained under
pathogen-free conditions with a 12:12 h light-dark cycle. All animal
care and experimental procedures were approved by the Animal Care
Committee of Old Dominion University. Three to six animals per
group received either vehicle (saline) or 1.6 mg/kg body wt LPS
intratracheally; 24 h later, mice were injected with 17-AAG (10 mg/kg
body wt) alone or in combination with Sirtinol (10 mg/kg body wt)
dissolved in 10% DMSO, intraperitoneally. Mice were killed 72 h
following LPS treatment, and bronchoalveolar lavage fluid was col-
lected to determine cellularity, as we have previously described (4).
Statistics. Data represent three to six independent experiments and
are reported as means  SE. Differences among groups were
analyzed by one-way ANOVA and post hoc tested with the
Tukey-Kramer multiple-comparison test. The t-test for indepen-
dent samples was used for comparisons between two groups.
Significance was accepted at P  0.05. Statistical calculations
were performed using GraphPad Prism 5.
RESULTS
Sirt-2-specific inhibitors selectively potentiate LPS-medi-
ated NF-B activation and target gene expression in
HLMVEC. HLMVEC were cotransduced with adeno-NF-B
luciferase reporter (10 MOI) and adeno-GFP viruses (100
MOI) and then treated with LPS (10 EU/ml) for 4 h in the
presence or absence of either a Sirt-1 inhibitor (10 M EX527)
or one of two Sirt-2 inhibitors (50 M sirtinol or 10 M
AGK2) (pretreated for 16 h). Sirt-2, but not Sirt-1, inhibitors
potentiated the NF-B promoter activation by LPS (Fig. 1A).
Additionally, HLMVEC were treated with 1 EU/ml LPS for 4
h in the presence and absence of the inhibitors. Real-time
qRT-PCR analysis revealed that only Sirt-2 inhibitors potenti-
ated the LPS-induced IKB mRNA induction (Fig. 1B). These
data suggest that Sirt-2 is the major isoform that acts as
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Fig. 1. Type 2 sirtuin (Sirt-2) suppresses NF-B transcriptional activation in human lung microvascular endothelial cells (HLMVEC). A: HLMVEC were
cotransduced with adeno-green fluorescent protein (GFP) and adeno-NF-B reporter luciferase viral particles. The cells were then treated with 10 EU/ml LPS
for 4 h in the absence or presence of the Sirt-1-specific inhibitor (10 M EX527) or of either one of the Sirt-2 selective inhibitors (50 M Sirtinol or 10 M
AGK2) (16 h pretreatment). Luciferase activity was determined in triplicate in equal volumes of cell lysates using a luminometer, normalized to the respective
GFP fluorescence, and plotted as fold change from untreated controls ( SE, n 	 3). B: HLMVEC were treated with 1 EU/ml LPS for 4 h in the absence or
presence of sirtuin inhibitors as in A. Total RNA was extracted and reverse transcribed as discussed in MATERIALS AND METHODS. The bar graph ( SE, n 	 3)
represents fold change in IKB mRNA expression from control. HLMVEC were transduced with either GFP control or Sirt-2 shRNA lentiviral particles, as
discussed in MATERIALS AND METHODS. C and D: the shRNA lentivirus-mediated downregulation of Sirt-2 protein and Sirt-2 mRNA expression by Western
blotting and TaqMan quantitative (q)RT-PCR, respectively. In E, 1 EU/ml LPS significantly induced more IKB mRNA expression compared with control
in wild-type cells and the downregulation of Sirt-2 significantly potentiated IKB mRNA induction by LPS compared with LPS-treated wild-type cells
( SE, n 	 3).
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suppressor of LPS-mediated NF-B transcriptional activation
in HLMVEC. To confirm its functional significance, Sirt-2
expression was downregulated in HLMVEC using shRNA
lentiviral particles. Sirt-2 expression in GFP- and Sirt-2
shRNA-transduced HLMVEC. There was significant reduction
in Sirt-2 expression and potentiation of LPS-induced IKB
mRNA expression in Sirt-2 knock-down cells (Fig. 1, C–E).
These data confirm that Sirt-2 predominantly acts as the neg-
ative regulator of LPS-induced NF-B transcriptional activa-
tion HLMVEC.
Hsp90 inhibitor suppresses NF-B activation via Sirt-2 in
human lung endothelial cells. The effect of hsp90 inhibition in
human lung endothelial cells is unique (31). The hsp90 inhib-
itor 17-AAG does not prevent the LPS-mediated NF-B nu-
clear translocation but attenuates NF-B activation and target
gene expression. To study whether Sirt-2 is involved in this
process, we treated HLMVEC with LPS along with 5 g/ml
17-AAG and sirtuin inhibitors for 16 h. Sirtinol potentiated the
LPS-induced NF-B activation and reversed the suppression of
LPS-induced NF-B reporter activation by 17-AAG (Fig. 2A).
Furthermore, qRT-PCR analysis showed that only Sirt-2 inhib-
itors (Sirtinol and AGK2) reversed the inhibitory effect of
17-AAG on NF-B target gene (IKB) mRNA induction by
LPS (1 EU/ml, 4 h), whereas the Sirt-1 inhibitor EX527 did not
(Fig. 2B). Moreover, Sirt-2 knock-down partially but signifi-
cantly recovered IKB mRNA expression in the presence of
17-AAG (Fig. 2C). The Sirt-2-dependent effect is also ob-
served in the induction of IL-8 mRNA (another well-known
NF-B target gene) by LPS and 17-AAG in HLMVEC (data
not shown).
Hsp90 inhibitor suppresses LPS-induced inflammation via
Sirt-2, in vivo. To confirm the above observations in vivo, we
employed the intratracheal LPS mouse model of acute lung
injury (ALI) that is characterized by severe alveolo-capillary
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Fig. 2. Sirt-2 inhibition reverses the repression of LPS-mediated NF-B activation and target gene expression by 17-AAG. A: adeno-GFP and adeno-NF-B
reporter luciferase viral particles were cotransduced as in Fig. 1. Cells were treated with LPS for 4 h in the absence and presence of 5 g/ml 17-AAG and 50
M Sirtinol (Sirt-2 selective inhibitor, together for 16 h, pretreatment). Luciferase activity ( SE, n	 3) was significantly increased by LPS; 17-AAG suppressed
the LPS effect, whereas Sirtinol potentiated the LPS effect and partially recovered the 17-AAG effect on LPS treatment in HLMVEC. B: TaqMan qRT-PCR
analysis ( SE, n 	 3) showed that LPS induced IKB mRNA expression; 17-AAG suppressed the LPS effect, the sirtuin inhibitor potentiated the LPS and
reversed the 17-AAG effect in HLMVEC. B (i), (ii), and (iii): 50 M Sirtinol-, 10 M AGK2-, and 10 M EX527-treated cells, respectively. C: Sirt-2 expression
was downregulated by Sirt-2 shRNA lentiviral particles in HLMVEC; cells were then treated with LPS in the presence and absence of 17-AAG. Bar graph (
SE) represents fold change in IKB mRNA expression in 1 of 3 independent experiments. LPS induced IKB mRNA expression in wild-type and potentiated
IKB mRNA expression in Sirt-2 knock-down HLMVEC; 17-AAG suppressed and partially but significantly reversed the effect of 17-AAG in Sirt-2
knock-down HLMVEC.
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inflammation. Figure 3 shows that LPS (1.6 mg/kg body wt
intratracheally) induced profound infiltration of immune cells
into C57BL/6 mouse lungs, as reflected in increased cellularity
of the bronchoalveolar lavage fluid (BALF). 17-AAG (10
mg/kg body wt intraperitoneal, 24 h posttreatment) signifi-
cantly reduced this hypercellularity. However, concurrent post-
treatment with Sirt-2 inhibitor (Sirtinol, 10 mg/kg body wt
intraperitoneal) potentiated BALF hypercellularity and signif-
icantly reversed the effect of 17-AAG. These data confirm that
Sirt-2 plays a critical role in the regulation of LPS-induced
lung inflammation in vivo.
Hsp90 inhibition induces Sirt-2 nuclear accumulation with-
out affecting Sirt-2 activity. A leucine-rich nuclear export
signal of Sirt-2 causes the localization of Sirt-2 both in the
cytoplasm and in the nucleus (17), suggesting that a nucleo-
cytoplasmic shuttling mechanism exists for Sirt-2. Hsp90 reg-
ulates the function of several nuclear import-export proteins
(23), so we investigated whether 17-AAG may perturb Sirt-2
cellular distribution. While a major portion of Sirt-2 was
expressed in the cytosolic fraction, a small but significant
amount was present in the nuclear fraction of HLMVEC. LPS
or 17-AAG alone did not change Sirt-2 distribution (Fig. 4A),
but there was a small but significant induction of nuclear Sirt-2
by LPS and 17-AAG together (Fig. 4, A and B). This obser-
vation was confirmed in immunocytochemistry/immunofluo-
rescence studies (Fig. 4C). It remains unclear how 17-AAG
and LPS affected this process. However, a more abundant
nuclear Sirt-2 should promote a robust transcriptional suppres-
sion. Next, to determine whether LPS and 17-AAG influence
Sirt-2 activity, HLMVEC were treated with 1 EU/ml LPS for
30 min in the presence and absence of 5 g/ml 17-AAG (16 h,
pretreatment). LPS induced total Sirt-2 activity (Fig. 4D), and
that was unaffected by 17-AAG. We also overexpressed Flag-
tagged human Sirt-2 in HeLa cells and performed coimmuno-
precipitation-immunoblotting (co-IP/IB) analysis. No direct
interaction between Sirt-2 and hsp90 was observed (Fig. 4E),
indicating that Sirt-2 is not a client of hsp90 and that it is thus
unlikely that hsp90 inhibition by 17-AAG would directly
influence Sirt-2 activity. In a parallel study, we overexpressed
Sirt-2 and PCAF (a bonafied Sirt-2 interacting protein) in HeLa
cells and observed their interaction, confirming that the ab-
sence of hsp90 in Sirt-2 immune complex was not due to
inappropriate techniques (data not shown).
Sirt-2 is not involved in the deacetylation of p65 in
HLMVEC. Sirt-2 has been reported to influence NF-B acti-
vation via deacetylation of K310 of p65 (21). To investigate
whether this also occurs in HLMVEC, we overexpressed
T7-tagged p65 adenovirus particles (31) in HLMVEC and then
treated them with 1 EU/ml LPS for 1 h in the presence or
absence of 5 g/ml 17-AAG (16 h pretreatment). LPS induced
p65 acetylation that was attenuated by 17-AAG (Fig. 5A).
Additionally, similarly treated HLMVEC were fixed in 1%
formaldehyde and sonicated to obtain 200 bp - 1.5 Kb chro-
matin fragments. We immunoprecipitated 14 –21 g chro-
matin with anti-p65 and acetyl-p65 K310 antibodies. The
eluted chromatin fragment was PCR-amplified with the
HIF-1 binding element of VEGF promoter serving as neg-
ative control. Acetylated p65K310 bound to the IKB
promoter; LPS induced p65 promoter binding but did not
further increase acetylated p65K310 binding; 17-AAG re-
duced both the basal as well as the LPS-induced binding of
both p65 and acetylated p65 (Fig. 5, B and C). Next, we
tested whether Sirt-2 interacted with p65. T7-/p65 adenovi-
rus and Flag-tagged Sirt-2 were co-overexpressed in
B16F10 mouse melanoma cells and HLMVEC. Cells were
then treated as before; T7-p65 was immunoprecipitated and
immunoblotted with anti-Flag antibody. No interaction was
observed between Sirt-2 and p65 (Fig. 5D). Thus, it appears
unlikely that Sirt-2 influences NF-B activation through p65
K310 deacetylation. We have previously demonstrated that
17-AAG suppresses LPS-induced CREB-binding protein
(CBP) histone acetylase (HAT) activity, without affecting
LPS-induced histone deacetylase (HDAC) activity. 17-AAG
also disrupted the LPS-induced interaction between p65 and
CBP coactivator in HLMVEC. These observations suggest
that p65-interacting HAT coactivators, rather than Sirt-2,
were the major contributors to LPS-induced p65 acetylation/
deacetylation.
Sirt-2 is recruited to NF-B target gene (IKB) promoter
and prevents transcription in HLMVEC. The Sirt-2 structure
does not contain a DNA-binding domain (27, 34), yet Sirt-2
binds near the transcription start site of the NEDD4 promoter
(16). Thus, Sirt-2 could influence IKB promoter activation
either directly or indirectly (via an epigenetic mechanism).
Using ChIP analysis, under basal conditions, we found that
Sirt-2 is recruited to the IKB promoter region (
178 to 65
bp). As expected, Sirt-1 did not bind to the promoter, and its
effect on IKB induction was negligible (Fig. 6A). LPS caused
core histone H3 displacement and Sirt-2 dissociation from the
promoter (Fig. 6, A, C, and D). This was followed by p65
recruitment at the same promoter region (Fig. 6A), which
contains three critical NF-B binding sites (12). Finally, there
was an enhanced binding of RNA Polymerase II (Fig. 6, A and
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Fig. 3. In vivo potentiation of LPS-induced lung inflammation by the Sirt-2-
specific inhibitor, Sirtinol, and reversal of the 17-AAG effect. C57BL/6 mice
(3–8 animals/group) received 1.6 mg LPS/kg body wt intratracheally. We
treated the mice, 24 h later, with 17-AAG (10 mg/kg body wt ip) either alone
or in combination with Sirtinol (10 mg/kg body wt). We determined lung
inflammation 72 h after LPS treatment from the degree of immune cell
infiltration into the lung by bronchoalveolar lavage (BAL). Means  SE of
BAL fluid (BALF) cellularity/ml.
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E), indicating activation of IKB gene transcription. 17-AAG
prevented the LPS-induced dissociation of core histone H3 and
Sirt-2 from the IKB promoter (Fig. 6, A, C, and D). We
therefore propose that the stability of Sirt-2/promoter interac-
tion could be the major factor determining the recruitment of
transcription factors and formation of RNA polymerase II
complex at the IKB promoter. The mutual exclusion of Sirt-2
and p65 from the IKB promoter could be due to the lack of
physical interaction between these two proteins. We also spec-
ulated that Sirt-2 and p65 are parts of two different complexes
with opposing influences on IKB promoter activation. Previ-
ously we have shown that, upon LPS treatment, p65 forms a
complex with CBP coactivator at the IKB promoter and that
the activator complex is destabilized and removed by 17-AAG
(31). Thus, we propose that an as yet unidentified factor forms
a repressor complex with Sirt-2.
Sirt-2 inhibitor reverses the 17-AAG effect and restores p65
and RNA pol II binding to the NF-B target gene (IKB)
promoter. To understand how Sirt-2 inhibitors affect Sirt-2
promoter recruitment we performed ChIP assays. Sirtinol de-
stabilized Sirt-2 promoter binding and reversed the 17-AAG-
induced binding stabilization (Fig. 7, A and C). Sirtinol also
reversed the 17-AAG effect and induced the displacement of
core histone H3 from the IKB promoter (Fig. 7, A and D).
Furthermore, Sirtinol promoted p65 (Fig. 7, A and B) and RNA
polymerase II (Fig. 7, A and E) recruitment to the promoter and
reversed the suppressive effect of 17-AAG. Thus, the cosup-
pressors recruited by 17-AAG at the NF-B target gene (IKB)
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Fig. 4. Heat shock protein (Hsp)90 inhibition does not alter LPS-induced total Sirt-2 activity but promotes nuclear accumulation of Sirt-2 in the presence of LPS.
HLMVEC were treated with LPS for 1 h in the presence and absence of 17-AAG (16 h, pretreatment). A: cytosolic and nuclear fractions were prepared and
cellular distribution of Sirt-2 was determined by Western blot analysis. Top: PARP nuclear expression served as nuclear loading control; bottom: -Tubulin
served as loading control. B: fold changes in nuclear and cytosolic Sirt-2 expression ( SE, n 	 3). The nuclear accumulation of Sirt-2 was significant only in
the presence of both 17-AAG and LPS. C: immunofluorescence staining of Sirt-2; representative ICC/IF image of Alexa 488-stained (green) Sirt-2 (top),
counterstained with DAPI (blue, middle), and a merged image (bottom). D: HLMVEC were treated with 1 EU/ml LPS for 30 min in the presence and absence
of 5 g/ml 17-AAG (16 h pretreatment). Sirt-2 was immunoprecipitated from the whole cell lysate, and Sirt-2 activation was determined, as discussed in
MATERIALS AND METHODS. Bar graph ( SE, n 	 3) represents fold Sirt-2 activity changes from untreated controls. Total Sirt-2 activity was induced by LPS and
17-AAG/LPS. 17-AAG did not affect LPS-induced total Sirt-2 activity. D: i: B16F10 mouse melanoma cells were cooverexpressed with T7-tagged p65
adenovirus and Flag-tagged Sirt-2 and treated as indicated. Cell lyaste was immunoprecipitated with anti-Flag antibody and immunoblotted with anti-T7 antibody.
ii: HLMVEC were infected with T7-tagged p65 adenovirus and treated as indicated. Cell lysate was immunoprecipitated with anti-T7 antibody and
immunoblotted with anti-Sirt-2 antibody. Sirt-2 and p65 did not coimmunoprecipitate. E: to investigate whether Sirt-2 is a client protein of hsp90, we performed
coimmunoprecipitation (co-IP) analysis using Flag-Sirt-2 overexpressing HeLa cells, as described in MATERIALS AND METHODS. Representative co-IP/immunoblots
(IB) indicate that there is no direct association between Sirt-2 and hsp90.
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promoter appears to require Sirt-2 activity. We have shown that
LPS removes Sirt-2 from the IKB promoter and, at the same
time, induces Sirt-2 activation in HLMVEC. While these obser-
vations may seem paradoxical, we believe that Sirt-2 activation
could be part of a negative feedback mechanism and that a prolific
cosuppressor complex is assembled only in the presence of 17-
AAG; this complex requires Sirt-2 activity to assemble on the
IKB promoter and prevent the recruitment and assembly of the
NF-B coactivator complex. The destabilization of p65-coactiva-
tors complex by 17-AAG further enhances cosuppressor complex
recruitment. In the absence of 17-AAG and of cosuppressors, the
NF-B coactivator complex is assembled unhindered at the pro-
moter, in response to LPS.
It is not clear how Sirt-2 is recruited at the NF-B target
gene promoters under basal conditions. To investigate a pos-
sible interaction between histone H3 and Sirt-2, co-IP/IB
analysis was performed. Sirt-2 physically interacts with histone
H3 (Fig. 7F). This suggests that Sirt-2 may be recruited to the
IKB promoter via its interaction with core histone H3.
Results from these studies are summarized in Fig. 7: Sirt-2 is
involved in the suppression of NF-B activation and NF-B target
gene (IKB) induction by inflammatory stimuli (e.g., LPS) in
HLMVEC. Under basal, unstimulated conditions, Sirt-2 is re-
cruited to the promoter via interaction with core histone H3 and
occupies the enhancer region of the promoter. Inflammatory
stimuli paradoxically enhance Sirt-2 activity, but this is counter-
acted the rapid induction in NF-B activity. Thus, Sirt-2 appears
to be a novel NF-B negative feedback regulator in HLMVEC.
LPS induces p65 nuclear transport and interaction with p300/CBP
coactivators. This interaction also enables p65 lysine acetylation
by p300/CBP HAT. Together, these events promote the displace-
ment of core histone H3 and Sirt-2 from the promoter region. The
p65 coactivator complex in turn recruits RNA Pol II to initiate
gene transcription. In the presence of hsp90 inhibitor, there is no
p65 coactivator complex formation and the hypoacetylated p65
alone is not sufficient to dissociate Sirt-2 from the promoter.
Additionally, the enhanced nuclear accumulation and the elevated
Sirt-2 activity in the presence of both LPS and 17-AAG further
stabilize Sirt-2/promoter interaction.
DISCUSSION
Hsp90 inhibitors are promising therapeutic agents because
of their ability to target multiple signaling pathways simulta-
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the IKB promoter.
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neously. These targets are mostly, but not exclusively, hsp90
client proteins, which number nearly 300 (23). The expression
and activity of these proteins are under the control of hsp90,
which, in turn, is intimately coupled to the 26S proteasome
(11). The inhibition of hsp90/client interaction by anti-hsp90
drugs leads to the destabilization, polyubiquitination, and deg-
radation of the client protein. Several key kinases and impor-
tant intermediates of NF-B signaling pathway, such as RIP
kinase, TAK-1 kinase, and IB kinases are hsp90 clients (23).
Consequently, the NF-B signaling pathway is highly sensitive
to hsp90 inhibitors. Hsp90 inhibition in most cell types leads to
disruption in NF-B signaling and prevents the nuclear trans-
location of NF-B proteins. Thus, anti hsp90 drugs have
potential as anti-inflammatory drugs.
Severe bacterial infection causes hyperactivation of NF-B
in the pulmonary endothelium. Hsp90 inhibition by 17-AAG
prevents LPS induced hyperpermeability and other pulmonary
complications in mice (5). We have previously shown that,
unlike in other cell types, in human pulmonary vascular endo-
thelium 17-AAG prevents NF-B transcriptional activation
without blocking NF-B nuclear translocation (31). Until now,
the mechanisms behind this observation remained unclear.
Of the seven sirtuin isoforms (Sirt-1 to -7), types 1, 2, and 6
have been implicated in the regulation of NF-B via direct
deacetylation of either p65 or acetyl histone H3 K9 (2, 17). Our
data confirm that Sirt-2 is the key regulator of NF-B activa-
tion in human lung endothelial cells. Sirt-2 did not affect p65
lysine acetylation and did not perturb NF-B signaling. How-
ever, it regulated the recruitment and binding of essential
factors at the target promoter. We discovered that Sirt-2 binds
to NF-B target gene (IKB) promoter under basal conditions.
The binding of Sirt-2 was associated with the suppression of
IKB promoter activity either basally or in the presence of
17-AAG. Other sirtuin isoforms, Sirt-1 and Sirt-6, did not bind
to IKB promoter (data not shown), and thus, their influence
was minimal. Either pharmacologic inhibition or shRNA-me-
diated Sirt-2 downregulation potentiated the effect of inflam-
matory challenge and reversed the suppression of IKB ex-
pression by 17-AAG.
We also observed that Sirt-2 is not an hsp90 client protein
and did not physically interact with hsp90. Thus, we did not
observe drastic changes in Sirt-2 activity by hsp90 inhibition.
However, hsp90 inhibitors induced accumulation of Sirt-2 in
the nucleus in stimulated (inflamed) cells. This suggested that
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Fig. 6. Direct association of Sirt-2 with the IKB promoter is responsible for the activation of NF-B-dependent transcription in HLMVEC. To investigate how Sirt-2
affects IKB promoter activity and the recruitment of other factors, we performed ChIP assays with treated HLMVEC, as in Fig. 4. A: a representative image of PCR
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Sirt-2, histone H3, and RNA Pol II, respectively. LPS induced p65 and RNA Pol II promoter binding but reduced Sirt-2 and histone H3 binding to the IKB promoter.
17-AAG blocked the LPS induced p65 binding, restored Sirt-2 and histone H3 binding and induced RNA Pol II binding to the IKB promoter.
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perhaps Sirt-2 nuclear import is facilitated by the combined
action of inflammation and hsp90 inhibition. The enhancement
of nuclear Sirt-2 accumulation in the presence of both LPS and
17-AAG likely helped sustain its inhibitory function at NF-B
target promoters.
The major NF-B negative feedback regulatory system is
via IKB induction (29). The instant induction of IKB by
NF-B activation causes IKB accumulation in the nucleus.
IKB-NF-B interaction is much more stringent than NF-B-
DNA interaction and effectively removes NF-B from the
promoter. This provides an efficient mechanism to terminate
NF-B signaling. Thus, the induction of Sirt-2 activity by LPS
adds another dimension to endothelial NF-B signaling. LPS
paradoxically induces both NF-B signaling and Sirt-2 activ-
ity. As Sirt-2 inhibition or knock-down potentiated NF-B
activation, we propose that Sirt-2 activation is a component of
a negative feedback regulatory mechanism of NF-B signal-
ing. Our study also suggested that Sirt-2 activity is essential for
keeping the NF-B target promoter in the closed conformation.
Sirtuins do not possess a DNA binding motif, and thus it is
not clearly understood how Sirt-2 is recruited to the IKB
promoter in the basal state. Perhaps chromatin-associated pro-
teins may be responsible for Sirt-2 binding. Although NF-B-
responsive promoters have hyperacetylated core histone H3
K9, the position of nucleosome at the enhancer region largely
determines the recruitment of NF-B subunits and subsequent
assembly of RNA Pol II initiation complex at the IKB
promoter (31). We have previously demonstrated that, under
basal conditions, core histone H3 masks the NF-B enhancer
elements of the IKB promoter. Upon inflammatory stimula-
tion, core histone H3 is displaced from the promoter to unmask
the enhancer region and permit NF-B binding. This is similar
to the pattern of Sirt-2 binding to the IKB promoter. Sirt-2
has been shown to interact with hyperacetylated histones H3
and H4 (21). Thus, we speculate that Sirt-2 binds to the IKB
promoter via its interaction with core histone H3. Whether
Sirt-2 requires other factors in addition to its interaction to
occupy the IKB enhancer region is not clear.
Alternatively, Sirt-2 is recruited to the promoter via a basal
co-repressor complex. The human IKB promoter exists in a
closed conformation in the unstimulated state. We have dem-
onstrated (MNase assay) that the IKB promoter region be-
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Fig. 7. The Sirt-2 selective inhibitor, sirtinol, counters the 17-AAG effect and stabilizes Sirt-2 promoter binding in HLMVEC. We performed ChIP assays with
HLMVEC treated with 17-AAG and LPS and increasing concentrations of sirtinol. A: a representative image of PCR products resolved on ethidium bromide
agarose gel. B–E: the quantification of data from A ( SE, n 	 3), expressed as fold changes in promoter binding of p65, Sirt-2, histone H3, and RNA Pol II,
respectively. LPS induced p65 and RNA Pol II promoter binding but reduced Sirt-2 and histone H3 binding to the IKB promoter. 17-AAG blocked the LPS
effects and this was restored by sirtinol, in a concentration-dependent manner. F: total HLMVEC lysate was immunoprecipitated with anti-Sirt-2 antibody and
immunoblotted with anti-histone H3 antibody. We observed coimmunoprecipitation of Sirt-2 and histone H3.
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comes accessible to MNase only in the presence of LPS (31).
This suggests that a basal suppressor complex is initially
assembled at the promoter possibly to prevent nonspecific gene
activation. Additionally, we have observed the existence of an
SWI/SNF suppressor complex at the IKB promoter, under
basal conditions (unpublished data). Hsp90 inhibitors revert
the open promoter conformation to the closed one, which no
longer is accessible to MNase, even in the presence of LPS.
The inability to displace core histone H3 from the promoter
in the presence of hsp90 inhibitor reduces IKB mRNA
expression. Thus, hsp90 inhibition perhaps favors the reassem-
bly of the Sirt-2/repressor complex at the promoter, which
cannot be displaced by LPS. One reason for that could be the
destabilization of NF-B/p300/CBP coactivator complex by
17-AAG (31). This destabilization affects the acetylation-
dependent NF-B/DNA interaction, as well as the recruitment
of other transcription factors to sustain RNA Pol II-dependent
transcription. The main difference between the basal and stim-
ulated states is the Sirt-2 activity status: total Sirt-2 activity is
lowered in the basal state compared with LPS stimulation.
Inhibition of Sirt-2 activity displaces the repressor complex
and promotes NF-B binding. However, this mechanism only
partly recovers NF-B activation and IKB mRNA expres-
sion. It is still not clear whether Sirt-2 inhibition restores the
disruption of NF-B/p300/CBP interaction by hsp90 inhibi-
tors. The proposed mechanism of hsp90-dependent NF-B
transcriptional activation and the role of Sirt-2 is summarized
in Fig. 8.
Pathological NF-B activation in the pulmonary microvas-
cular endothelium is under the control of hsp90. We now
demonstrate a novel mechanism, one that is unique to human
pulmonary endothelium, namely the involvement of Sirtuins
and especially Sirt-2. As discussed elsewhere, hsp90 inhibition
blocks IKB kinase activation and restores inhibitory IKB
protein in several other cell types (31). This is considered the
universal negative regulatory mechanism that blocks NF-B
target gene expression (10, 29). However, in HLMVEC, hsp90
inhibition does not prevent NF-B nuclear translocation in
response to LPS. As the availability of active NF-B proteins
in the nucleus becomes sufficient to induce target promoters,
human lung microvascular endothelia appear to have evolve a
secondary regulatory mechanism, via Sirt-2. As we demon-
strate here, Sirt-2 plays the crucial role of the NF-B transcrip-
tional inhibitor in the lung microvasculature. Our in vivo data
also confirm the physiological role of Sirt-2 in LPS-induced
lung inflammation in mice, which has been directly correlated
to abnormal NF-B induction (1, 15, 22). It is intriguing to
consider that drugs that modulate Sirt-2 function could have
therapeutic potential for sepsis and acute lung inflammatory
diseases.
Sirt-2
H3
p65
Hsp90
Basal
1. Sirt-2 (low activity) binding basal promoter
via interaction with core histone H3
2. Core H3 masking NF-κB enhancer element   
(Shown as Red region)
No Transcription 
1. Hsp90-dependent p65-p300/CBP 
co-activator complex formation 
2. p65 Lys-Acetylation (Ac) by p300/CBP
(high HAT activity)
3. Sirt-2 (high activity) and core histone H3
displacement from promoter
4. p65 occupies NF-κB enhancer element
5. Assembly of RNA Pol II initiation complex 
Induction of Transcription
1. p65-p300/CBP complex dissociation by Hsp90 inhibitor 
2. p65 Lys-hypoacetylation (low HAT activity)
3. Sirt-2 (high activity) prevents p65 promoter binding
4. Hsp90-dependent stabilization of 
Sirt-2/promoter interaction
Suppression of Transcription
p300/CBP
Sirt-2
H3
RNA 
Pol II
InflammationInflammation
x x
NF-κB Target Promoter NF-κB Target Promoter NF-κB Target Promoter
Hsp90
Sirt-2
H3
p300/CBP
Ac
p65
17-AAG
p300/CBP
Ac
p65
Sirt-2
H3
Fig. 8. Schematic representation of suppression of inflammation-induced NF-B target gene promoter activation by hsp90 inhibitors via Sirt-2.
L973Hsp90 REGULATES NF-B VIA Sirt-2
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00054.2016 • www.ajplung.org
 by 10.220.33.4 on M
ay 26, 2017
http://ajplung.physiology.org/
D
ow
nloaded from
 
ACKNOWLEDGMENTS
We thank Drs. Loree Heller and Ardrei Pakhomov of Old Dominion
University, Norfolk, VA, for kindly providing B16F10 Mouse melanoma cells
and HeLa human cervical cancer cells, respectively.
GRANTS
This work was funded by National Heart, Lung, and Blood Institute Grant
HL-093460.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
G.S.T., C.B., N.B., B.W.G., M.A.C., J.R.N., D.J.F., and J.D.C. conception
and design of research; G.S.T., C.B., N.B., B.W.G., and M.A.C. performed
experiments; G.S.T., C.B., N.B., B.W.G., M.A.C., J.R.N., D.J.F., and J.D.C.
analyzed data; G.S.T., C.B., N.B., B.W.G., M.A.C., J.R.N., D.J.F., and J.D.C.
interpreted results of experiments; G.S.T., C.B., and N.B. prepared figures;
G.S.T. drafted manuscript; G.S.T. and J.D.C. edited and revised manuscript;
G.S.T., C.B., N.B., B.W.G., M.A.C., J.R.N., D.J.F., and J.D.C. approved final
version of manuscript.
REFERENCES
1. Abraham E. Nuclear factor-kappaB and its role in sepsis-associated organ
failure. J Infect Dis 178: S364–S369, 2003.
2. Bagul PK, Deepthi N, Sultana R, Banerjee SK. Resveratrol ameliorates
cardiac oxidative stress in diabetes through deacetylation of NFkB-p65
and histone 3. J Nutr Biochem 26: 1298–1307, 2015.
3. Catravas JD, Snead C, Dimitropoulou C, Chang AS, Lucas R, Verin
AD, Black SM. Harvesting, identification and barrier function of human
lung microvascular endothelial cells. Vascul Pharmacol 52: 175–181,
2010.
4. Chatterjee A, Dimitropoulou C, Drakopanayiotakis F, Antonova G,
Snead C, Cannon J, Venema RC, Catravas JD. Heat shock protein 90
inhibitors prolong survival, attenuate inflammation, and reduce lung injury
in murine sepsis. Am J Respir Crit Care Med 176: 667–675, 2007.
5. Chatterjee A, Snead C, Yetik-Anacak G, Antonova G, Zeng J, Catra-
vas JD. Heat shock protein 90 inhibitors attenuate LPS-induced endothe-
lial hyperpermeability. Am J Physiol Lung Cell Mol Physiol 294: L755–
L763, 2008.
6. Dauphinee SM, Karsan A. Lipopolysaccharide signaling in endothelial
cells. Lab Invest 86: 9–22, 2006.
7. Favero G, Franceschetti L, Rodella LF, Rezzani R. Sirtuins, aging, and
cardiovascular risks. Age (Dordr) 37: 9804, 2015.
8. Gao Z, Chiao P, Zhang X, Zhang X, Lazar MA, Seto E, Young HA, Ye
J. Coactivators and corepressors of NF-kappaB in IkappaB alpha gene
promoter. J Biol Chem 280: 21091–21098, 2005.
9. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T.
CREB-binding protein/p300 are transcriptional coactivators of p65. Proc
Natl Acad Sci USA 94: 2927–2932, 1997.
10. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 18: 2195–
2224, 2004.
11. Imai J, Maruya M, Yashiroda H, Yahara I, Tanaka K. The molecular
chaperone Hsp90 plays a role in the assembly and maintenance of the 26S
proteasome. EMBO J 22: 3557–3567, 2003.
12. Ito CY, Kazantsev AG, Baldwin AS Jr. Three NF-kappa B sites in the
I kappa B-alpha promoter are required for induction of gene expression by
TNF alpha. Nucleic Acids Res 22: 3787–3792, 1994.
13. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends
Mol Med 13: 460–469, 2007.
14. Kim JW, Jang SM, Kim CH, An JH, Kang EJ, Choi KH. New
molecular bridge between RelA/p65 and NF-kappaB target genes via
histone acetyltransferase TIP60 cofactor. J Biol Chem 287: 7780–7791,
2012.
15. Li X, Su J, Cui X, Li Y, Barochia A, Eichaker PQ. Can we predict the
effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and
ethyl pyruvate. Expert Opin Investig Drugs 18: 1047–1060, 2009.
16. Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D,
Su SP, Nelson C, Chang DK, Koach J, Tee AE, Haber M, Norris MD,
Toon C, Rooman I, Xue C, Cheung BB, Kumar S, Marshall GM,
Biankin AV, Liu T. The histone deacetylase SIRT2 stabilizes Myc
oncoproteins. Cell Death Differ 20: 503–514, 2012.
17. Liu TF, Vachharajani V, Millet P, Bharadwaj MS, Molina AJ, McCall
CE. Sequential actions of SIRT1-RELB-SIRT3 coordinate nuclear-mito-
chondrial communication during immunometabolic adaptation to acute
inflammation and sepsis. J Biol Chem 290: 396–408, 2014.
18. Martinez-Redondo P, Vaquero A. The diversity of histone versus
nonhistone sirtuin substrates. Genes Cancer 4: 148–163, 2013.
19. Natoli G. NF-kappaB and chromatin: ten years on the path from basic
mechanisms to candidate drugs. Immunol Rev 246: 183–192, 2012.
20. Newton R, Holden NS. Separating transrepression and transactivation: a
distressing divorce for the glucocorticoid receptor? Mol Pharmacol 72:
799–809, 2007.
21. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human
Sir2 ortholog, SIRT2, is an NAD-dependent tubulin deacetylase. Mol
Cell 11: 437–444, 2003.
22. Orfanos SE, Mavrommati I, Korovesi I, & Roussos C. Pulmonary
endothelium in acute lung injury: from basic science to the critically ill.
Intensive Care Med 30: 1702–1714, 2004.
23. Picard D. Hsp90 Interactors. http://www.picard.ch/downloads/
Hsp90interactors.pdf (last accessed on Dec. 21, 2015).
24. Poulose N, Raju R. Sirtuin regulation in aging and injury. Biochim
Biophys Acta 1852: 2442–55, 2015.
25. Reber L, Vermeulen L, Haegeman G, Frossard N. Ser276 phosphory-
lation of NF-kB p65 by MSK1 controls SCF expression in inflammation.
PLoS One 4: e4393, 2009.
26. Rothgiesser KM, Erener S, Waibel S, Luscher B, Hottiger MO. SIRT2
regulates NF-kappaB dependent gene expression through deacetylation of
p65 Lys310. J Cell Sci 123: 4251–4258, 2010.
27. Sanders BD, Jackson B, Marmorstein R. Structural basis for sirtuin
function: what we know and what we don’t. Biochim Biophys Acta 1804:
1604–1616, 2009.
28. Sapountzi V, Logan IR, Robson CN. Cellular functions of TIP60. Int J
Biochem Cell Biol 38: 1496–1509, 2006.
29. Scott ML, Fujita T, Liou HC, Nolan GP, Baltimore D. The p65 subunit
of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes
Dev 7: 1266–1276, 1993.
30. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E,
Westin S, Thanos D, Rosenfeld MG, Glass CK, Collins T. Transcrip-
tional activation by NF-kappaB requires multiple coactivators. Mol Cell
Biol 19: 6367–6378, 1999.
31. Thangjam GS, Dimitropoulou C, Joshi AD, Barabutis N, Shaw MC,
Kovalenkov Y, Wallace CM, Fulton DJ, Patel V, Catravas JD. Novel
mechanism of attenuation of LPS-induced NF-kappaB activation by the
heat shock protein 90 inhibitor, 17-N-allylamino-17-demethoxygeldana-
mycin, in human lung microvascular endothelial cells. Am J Respir Cell
Mol Biol 50: 942–952, 2014.
32. Wan F, Lenardo MJ. Specification of DNA binding activity of NF-
kappaB proteins. Cold Spring Harb Perspect Biol 1: a000067, 2009.
33. Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of
sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J 36:
3404–3412, 2015.
34. Yuan H, Marmorstein R. Structural basis for sirtuin activity and inhibi-
tion. J Biol Chem 287: 42428–42435, 2012.
35. Zhang Q, Malik P, Pandey D, Gupta S, Jagnandan D, Belin de
Chantemele E, Banif B, Marrero MB, Rudic RD, Stepp DW, Fulton
DJ. Paradoxical activation of endothelial nitric oxide synthase by NADPH
oxidase. Arterioscler Thromb Vasc Biol 28: 1627–1633, 2008.
36. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by
PKA stimulates transcriptional activity by promoting a novel bivalent
interaction with the coactivator CBP/p300. Mol Cell 1: 661–671, 1998.
L974 Hsp90 REGULATES NF-B VIA Sirt-2
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00054.2016 • www.ajplung.org
 by 10.220.33.4 on M
ay 26, 2017
http://ajplung.physiology.org/
D
ow
nloaded from
 
